Significant efficacy across multiple endpoints

UP TO
81%
REDUCTION
IN SEVERE
EXACERBATIONS1,b
See Results
UP TO
480mL
IMPROVEMENT
IN LUNG FUNCTION1,c
See Results
 
86%
OF PATIENTS
REDUCED OR ELIMINATED THEIR OCS DOSE5,d
See Results

bWith DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood EOS
≥300 cells/μL (DRI12544, secondary endpoint).

cAt Week 52 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL improvement with placebo + SOC (n=142) in patients with baseline blood EOS ≥300 cells/μL (QUEST, secondary endpoint).

dAt Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (VENTURE, ITT population).

EOS, eosinophils; ITT, intention-to-treat; OCS, oral corticosteroid; SOC, standard of care.

Mechanism of Action
(MOA)

Only DUPIXENT targets
both IL-4 and IL-13
signaling, two key sources
of local and systemic type
2 inflammation1-3,a

EXPLORE THE MOA

aThe mechanism of dupilumab action has not
been definitively established.1

Long-term Efficacy and
Safety Data

Explore the TRAVERSE
open-label extension (OLE)
study and see up to ~3
years of efficacy and safety
data6

SEE THE DATA

Safety Data

View safety data across
clinical trials

SEE safety DATA

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

DUPIXENT MyWay
ENROLLMENT FORMS

FOR ALLERGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ENT SPECIALISTS/PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form
NO BIOMARKER
TESTING REQUIRED

for 99% of OCS-dependent asthma patients who are commercially insured7

Check Formulary Status in Your Area

See the insurance coverage status, prior authorization, and step edit information for DUPIXENT.

Look up coverage